S&P 500 may face selling pressure as systematic funds reach full exposure
SAN DIEGO - Neurocrine Biosciences, Inc. (NASDAQ:NBIX), a biopharmaceutical company with a market capitalization of $11.9 billion and impressive revenue growth of 21.7% over the last twelve months, announced findings from a Phase 4 study indicating that patients with tardive dyskinesia continued to show improvements in functional and health-related quality of life measures after treatment with INGREZZA® (valbenazine) capsules. The data was presented at the International Society for Pharmacoeconomics and Outcomes Research Conference in Montreal, Canada. According to InvestingPro data, the company maintains a strong financial health score of "GREAT," supporting its continued investment in clinical research.
The study involved 127 patients who were initially treated with up to 80 mg of INGREZZA for eight weeks. Following this period, they were randomized to either continue with the medication or switch to a placebo for another eight weeks. Health-related quality of life was measured using the EuroQol 5-Dimension 5-Level (EQ-5D-5L) and the Sheehan Disability Scale (SDS). The company’s robust gross profit margin of 63.9% demonstrates its efficient drug development and commercialization capabilities.
Results showed that patients who continued INGREZZA treatment experienced significant improvements in mobility, self-care, usual activities, and pain/discomfort. Notably, compared to those on placebo, these patients also reported significant improvements in anxiety/depression and in functional areas like work/school, social life, and family/home life.
With nine analysts recently revising their earnings estimates upward, Eiry W. Roberts, M.D., Chief Medical Officer of Neurocrine Biosciences, emphasized the importance of these findings, stating that they add to the evidence supporting INGREZZA’s potential to significantly improve the quality of life for tardive dyskinesia patients. For detailed financial analysis and additional insights, investors can access the comprehensive Pro Research Report available on InvestingPro.
Tardive dyskinesia is a movement disorder characterized by uncontrollable, abnormal movements that can disrupt daily life and negatively impact patients. INGREZZA, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, is approved in the U.S. for treating adults with tardive dyskinesia and chorea associated with Huntington’s disease.
The company also discussed other presentations at the ISPOR meeting, including studies on real-world dosing patterns for VMAT2 inhibitors, disparities in tardive dyskinesia diagnosis and treatment, and the impact of glucocorticoid dose on clinical outcomes in congenital adrenal hyperplasia. Trading at a P/E ratio of 39.31, Neurocrine Biosciences continues to demonstrate strong market performance, with its stock showing resilience in recent market conditions.
The information in this article is based on a press release statement from Neurocrine Biosciences.
In other recent news, Neurocrine Biosciences has been the focus of several analyst updates following its first-quarter results for 2025. Cantor Fitzgerald maintained an Overweight rating with a $170 price target, despite reducing the terminal growth rate for the company. The firm remains optimistic about the future revenue prospects for Neurocrine’s key products, Ingrezza and Crenessity. UBS raised its price target from $137 to $152, maintaining a Buy rating, and highlighted the potential of Ingrezza and the upcoming Crenessity launch.
Stifel analysts also sustained a Buy rating and a $166 target, citing strong performances from Ingrezza and a promising start for Crenessity, which exceeded initial expectations. RBC Capital Markets increased its price target to $145, noting surprising commercial momentum and solid sales figures for Ingrezza. Meanwhile, BMO Capital Markets raised its target from $96 to $115, acknowledging Crenessity’s early success but expressing caution regarding future challenges for Ingrezza. These developments suggest that Neurocrine Biosciences is navigating a complex landscape with its product portfolio, drawing varied but generally positive assessments from analysts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.